Q4 2025 RenovoRx Inc Earnings Call Transcript
Key Points
- RenovoRx Inc (RNXT) reported over $1 million in revenue for 2025, marking strong initial adoption of RenovoCath.
- The company has expanded its network to 12 active commercial cancer centers, with 21 additional centers evaluating or preparing for activation.
- RenovoRx Inc (RNXT) has a robust pipeline with plans to triple its commercial footprint to 36 active sites by the end of 2026.
- The company has successfully completed over 700 procedures using RenovoCath, supported by FDA 510(k) clearance.
- RenovoRx Inc (RNXT) closed an oversubscribed private placement, raising approximately $10 million to support commercial expansion and clinical development.
- Quarterly revenue is subject to variability due to the small number of active commercial centers.
- The transition of TIGeR-PaC trial centers to commercial use is ongoing, with some centers preferring to complete trial enrollment first.
- The company faces challenges in scaling operations quickly due to the need for internal approvals and patient identification at new centers.
- There is a 20-35% dropout rate during the induction phase of the TIGeR-PaC trial, affecting patient randomization timelines.
- RenovoRx Inc (RNXT) is not providing specific revenue guidance for Q1 2026, indicating uncertainty in short-term financial projections.
Good afternoon. I'll be your conference call operator today. Please note that today's call is being recorded, and all participants other than management are in listen-only mode.
There will be a Q&A session following management's presentation.
I'll now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead.
Thank you, operator. Good afternoon, everyone, and welcome to RenovoRx's fourth-quarter and full-year 2025 financial results conference call. I'm joined today by members of our leadership team, including Dr. Ramtin Agah, Executive Chair and Founder; Shaun Bagai, Chief Executive Office; and Mark Voll, Chief Financial Officer.
Before we begin, I'd like to remind everyone the statements made during today's call may contain forward-looking statements covered by the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
